Hua Lingyang, Juratli Tareq A, Zhu Hongda, Deng Jiaojiao, Wang Daijun, Sun Shuchen, Xie Qing, Wakimoto Hiroaki, Gong Ye
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Neurosurgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Front Oncol. 2020 Sep 18;10:542294. doi: 10.3389/fonc.2020.542294. eCollection 2020.
Studies have shown mitochondrial genome content (mtDNA content) varies in many malignancies. However, its distribution and prognostic values in high-grade meningioma remain largely unknown. In this retrospective study, we sought to assess a putative correlation between the mtDNA content and clinical characteristics. Mitochondrial DNA was extracted from 87 World Health Organization grade III meningioma samples using a qPCR method. The distribution of mtDNA content in WHO grade III meningioma and its correlations with clinical variables were assessed. Furthermore, we prognostic values were also determined. Mean mtDNA content was 617.7 (range, 0.8-3000). There was no mtDNA distribution difference based on the histological subtypes ( = 0.07). Tumors with preoperative radiation were associated with lower mtDNA content ( = 0.041), whereas no correlations with other clinical variables were observed. A high mtDNA content was associated with significantly better PFS ( = 0.044) and OS ( = 0.019). However, in patients who received postoperative radiotherapy, low mtDNA content was associated with better PFS ( = 0.028), while no difference in OS was observed ( = 0.272). Low mtDNA content was also associated with better OS and PFS in subgroups of patients with ER negative status (PFS, = 0.002; OS, = 0.002). Consistent with other tumors, high mtDNA content was associated with better outcome in WHO grade III meningioma in our cohort. However, for patients who received post-operative radiation therapy, low mtDNA content was associated with better PFS. These findings suggest that mtDNA content may further be explored as a potential biomarker for high-grade meningioma patients and for those who received postoperative radiation therapy.
研究表明，线粒体基因组含量（mtDNA含量）在许多恶性肿瘤中存在差异。然而，其在高级别脑膜瘤中的分布及预后价值仍 largely unknown。在这项回顾性研究中，我们试图评估mtDNA含量与临床特征之间的假定相关性。使用qPCR方法从87例世界卫生组织III级脑膜瘤样本中提取线粒体DNA。评估了WHO III级脑膜瘤中mtDNA含量的分布及其与临床变量的相关性。此外，还确定了预后价值。mtDNA平均含量为617.7（范围为0.8 - 3000）。基于组织学亚型，mtDNA分布无差异（= 0.07）。术前接受放疗的肿瘤与较低的mtDNA含量相关（= 0.041），而未观察到与其他临床变量的相关性。高mtDNA含量与显著更好的无进展生存期（PFS，= 0.044）和总生存期（OS，= 0.019）相关。然而，在接受术后放疗的患者中，低mtDNA含量与更好的PFS相关（= 0.028），而OS无差异（= 0.272）。低mtDNA含量在雌激素受体阴性状态患者亚组中也与更好的OS和PFS相关（PFS，= 0.002；OS，= 0.002）。与其他肿瘤一致，在我们的队列中，高mtDNA含量与WHO III级脑膜瘤的更好预后相关。然而，对于接受术后放疗的患者，低mtDNA含量与更好的PFS相关。这些发现表明，mtDNA含量可能进一步被探索作为高级别脑膜瘤患者以及接受术后放疗患者的潜在生物标志物。
